Có gì mới trong cơn đau thần kinh?

Farrar JT, Portenoy RK (2001) Neuropathic cancer pain: the role of adjuvant analgesics. Oncology 15(11):1435–1442 Woolf CJ, Mannion RJ (1999) Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet 353:1959–1964 Colombo B, Annovazzi POL, Comi G (2006) Medications for neuropathic pain: current trends. Neurol Sci 27:S183–S189 Rowbotham M (2005) Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 65:S66–S73 Harden N, Cohen M (2003) Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 25:S12–S17 Finnerup NB, Johannesen IL, Sindrup SH, Bach FW, Jensen TS (2001) Pain and dysesthesia in patients with spinal cord injury: a postal survey. Spinal Cord 39(5):256–262 Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfield CA (1997) Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain 13(4):324–329 Davies HT, Crombie IK, Macrae WA (1994) Why use a pain clinic? Management of neurogenic pain before and after a referral. J R Soc Med 87(7):382–385 Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ (2001) When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 54(3):253–262 Farrar J, Young JP Jr, LaMoreaux L, Werth J, Poole M (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158 Rowbotham M (2001) What is a clinically meaningful reduction in pain? Pain 94(2):131–132 Dubinsky RM, K.H, El-Chami Z, Boutwell C, Ali H (2004) Quality standards subcommittee of the American academy of neurology, practice parameter: treatment of postherpetic neuralgia: an evidence based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 63(6):959–965 Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88(3):287–294 Truini A, Cruccu G (2006) Pathophysiological mechanisms of neuropathic pain. Neurol Sci S179–S182 Ueda H (2006) Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 109:57–77 Porreca F, Tang QB, Bian D, Riedl M, Elde R, Lai J (1998) Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. Brain Res 795:197–203 Nichols ML, Lopez Y, Ossipov MH, Bian D, Porreca F (1997) Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1–13) or MK-801 in a nerve ligation model of peripheral neuropathy. Pain 69:317–322 Woolf CJ, Shortland P, Coggeshall RE (1992) Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 355:75–78 Moore Ka, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ (2002) Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 22(15):6724–6731 Ren K, Dubner R (2002) Descending modulation in persistent pain: an update. Pain 100:1–6 Birklein F, Rowbotham MC (2005) Does pain change the brain? Neurology 65:666–667 Sindrup SH, Jensen TS (2002) Pharmacotherapy of trigeminal neuralgia. Clin J Pain 18(1):22–27 Eisenberg E, McNicol ED, Carr D (2005) Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin. JAMA 293:3043–3052 Hollingshead J, Dühmke RM, Cornblath D (2006) Tramadol for neuropathic pain. Cochrane Database Syst Rev 3(CD003726) (in press) Desmeules JA (2000) The tramadol option. Eur J Pain 4(Suppl A):15–21 Mattia C, Coluzzi F (2005) Tramadol. Focus on musculoskeletal and neuropathic pain. Minerva Anestesiol 71(10):565–584 Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43(13):879–923 Mittino D, Mula M, Monaco F (2004) Serotonin syndrome associated with tramadol sertraline coadministration. Clin Neuropharmacol 27(3):150 Houlihan D (2004) Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 38(3):411–413 Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS (1999) Tramadol relieves pain and allodynia in polyneuropathy: a randomized, double blind controlled trial. Pain 83(1):85–90 Davis M (2005) Buprenorphine in cancer pain. Support Care Cancer 13(11):878–887 Radbruch L (2003) Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract Suppl 19–22 Sittl R (2006) Transdermal buprenorphine in cancer pain and palliative care. Palliat Med (20):s25–s30 Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55(5):569–580 Dahan A (2006) Opioid induced respiratory effects: new data on buprenorphine. Palliat Med (20(S)):s3–s8 Kouya PF, Hao JX, Xu XJ (2002) Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol 16(450):49–53 Christoph T, Kogel B, Schiene K, Meen M, DeVry J, Friderichs E (2005) Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507:87–98 Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M, Schuttler J (2005) Different profiles of buprenorphine induced analgesia and antihyperalgesic in a human pain model. Pain 118:15–22 Simonnet G (2005) Opioids: from analgesia to antihyperalgesia? Pain 118:8–9 Meyer RR, S.S, Kieser S, Magerl W, Roehrig J, Duenges B et al (2005) Methadone and levomethadone similarly reduce pain and hyperalgesia in a human pain model. World Congress of Pain Davis JL, Lewis SB, Gerich JE, Kaplan RA, Schultz TA, Wallin JD (1977) Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. JAMA 238(21):2291–2292 Sindrup SH, Otto M, Finnerup NB, Jensen TS (2005) Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 96:399–409 McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PH, Moore RA (1996) A systematic review of antidepressants in neuropathic pain. Pain 68:217–227 Mattia C, Coluzzi F (2003) Antidepressants in chronic neuropathic pain. Mini Rev Med Chem 3(7):773–784 Bohn LM, Xu F, Gainetdinov RR, Caron MG (2000) Potentiated opioid analgesia in norepinephrine transporter knock out mice. J Neurosci 20(24):9040–9045 Yokogawa F, Kiuchi Y, Ishikawa Y, Otsuka N, Masuda Y, Oguchi K, Hosoyamada A (2002) An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 95(1):163–168 Ghelardini C, Galeotti N, Bartolini A (2000) Antinociception induced by amitriptyline and imipramine is mediated by alpha2A-adrenoceptors. Jpn J Pharmacol 82(2):130–137 Goldstein DJ, Lu Y, Detke M, Lee TC, Iyengr S (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116:109–118 Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, Wernicke JF (2005) A double blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med (5):346–356 Barkin RL, Barkin S (2005) The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 12:431–438 Wu EQ, Birnbaum HG, Marva MN, LeTK, Robinson RL, Rosen A, Gelwicks S (2006) Cost effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 7(6):399–407 Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60(8):1284–1289 Davis JL, Smith RL (1999) Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care 22(11):1909–1910 Kiayias JA, Vlachou ED, Lakka-Papadodima E (2000) Venlafaxine HCl in the treatment of painful peripheral diabetic neuropathy. Diabetes Care 23(5):699 Taylor K, Rowbotham MC (1996) Venlafaxine hydrochloride and chronic pain. West J Med 165(3):147–148 Lithner F (2000) Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. Diabetes Care 23(11):1710–1711 Sumpton JE, Moulin DE (2001) Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 35(5):557–559 Tasmuth T, Hartel B, Kalso E (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6(1):17–24 Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E (2004) Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 18(2):131–137 Suzuki R, Rahman W, Rygh L, Webber M, Hunt S, Dickenson A (2005) Spinal supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain 117:292–303 Gu Y, Huang LY (2002) Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. Neuroscience Letters 324:177–180 Wheeler G (2002) Gabapentin. Pfizer. Curr Opin Investig Drugs 3(3):470–477 Rose MA, Kam PC (2002) Gabapentin: pharmacology and its use in pain management. Anaesthesia 451–462 Perucca E (1999) The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 40:S1–S13 Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, Reece PA (1994) Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56(2):154–159 Fischer JH, Barr AN, Rogers SL, Fischer PA, Trudeau VL (1994) Lack of serious toxicity following gabapentin overdose. Neurology 44(5):982–983 Parsons B, Tive L, Huang S (2004) Gabapentin a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. Am J Geriatr Pharmacother (3):157–162 Bennett M (2004) Gabapentin in the treatment of neuropathic pain. Palliat Med 18(5):5–11 Backonja M, Glanzman RL (2003) Gabapentin dosing for neuropathic pain: evidence from randomized placebo controlled clinical trials. Clin Ther 25:81–104 Serpell MG, Neuropathic Pain Study Group (2002) Gabapentin in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 99(3):557–566 Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280(21):1831–1836 Mellegers MA, Furlan AD, Mailis A (2001) Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain 17:284–295 Wiffen PJ, McQuay HJ, Edwards JE, Moore RA (2005) Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 3 Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D (1998) Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol 40(4):191–200 Gottrup H, Juhl G, Kristensen A, Lai R et al (2004) Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 101:1400–1408 Dallocchio C, Buffa C, Mazzarello P, Chiroli S (2000) Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open label pilot study. J Pain Symptom Manage 20(4):280–285 Sills G (2006) The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6:108–113 Guay D (2005) Pregabalin in neuropathic pain: a more “pharmaceutically elegant” gabapentin? Am J Geriatr Pharmacother 3(4):274–286 Frampton JE, Foster RH (2005) Pregabalin in the treatment of postherpetic neuralgia. Drugs 65(1):111–118 Rosenstock J, Tuchman M, LaMoreaux L, Sharma U (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double blind placebo controlled trial. Pain 110(3):628–638 Lesser H, Sharma U, LaMoreaux L, Poole RM (2004) Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63(11):2104–2110 Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo controlled trial. J Pain 6(4):253–260 Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post herpetic neuralgia: results of a randomized, placebo controlled clinical trial. Pain 109(1–2):26–35 Dworkin RH, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM (2003) Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60(8):1274–1283 Dworkin RH, Kirkpatrick P (2005) Pregabalin. Nat Rev Drug Discov 4(6):455–456 No authors listed (2005) Pregabalin: a new drug. Very similar to gabapentin. Prescrire Int 14(80):203–206 Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 289–305 Ilse W (2002) Neuropathic pain: mechanisms, diagnosis and treatment. Can J CME Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J (2004) A treatment algorithm for neuropathic pain. Clin Ther 26(7):951–979 Solaro C, Mesmer Uccelli M, Uccelli A, Leandri M, Mancardi GL (2000) Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol 44(1):45–48 Gilron I, Max MB (2005) Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 5(6):823–830 Matthews EA, Dickenson AH (2002) A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology 96(3):633–640 Tseng LL, Tang R (1989) Differential actions of the blockade of spinal opioid, adrenergic and serotonergic receptors on the tail flick inhibition induced by morphine microinjected into dorsal raphe and central gray in rats. Neuroscience 33(1):93–100 Crisp T, Smith DJ (1989) A local serotonergic component involved in the spinal antinociceptive action of morphine. Neuropharmacology 28(10):1047–1053 Gray AM, Spencer PSJ, Sewell RDE (1998) The involvement of the opioidergic system in the nociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 124:669–674 Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A (2002) Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double blind crossover study. Tumori 883:239–42 Gordon NC, Heller PH, Gear RW, Levine JD (1993) Temporal factors in the enhancement of morphine analgesia by desipramine. Pain 53(3):273–276 Gilron I, Bailey JM, Tu D, Holden RR, Weavre DF, Houlden RL (2005) Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352(13):1324–1334 Backonja MM, Irving G, Argoff C (2006) Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 10:34–38 Przewlocki R, Przewlocka B (2005) Opioids in neuropathic pain. Curr Pharm Des 11:3013–3025 Wu G, Lu Z-H, Wei TJ, Howells RD, Christoffers K, Ledeen W (1998) The role of GM1 ganglioside in regulating excitatory opioid effects. Ann N Y Acad Sci 845:126–138 Morris RM (2004) Spinal dorsal horn neuron targets for nociceptive primary afferents: do single neuron morphological characteristics suggest how nociceptive information is processed at the spinal level. Brain Res Rev 46:173–190